Can a diabetes pill fix antipsychotic weight gain?
NCT ID NCT05669742
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding empagliflozin, a diabetes drug, can reduce weight gain and other metabolic side effects caused by olanzapine in people with schizophrenia. Forty adults aged 18 to 60 who take olanzapine will receive either empagliflozin or a placebo for several weeks. The main goal is to see if the drug helps control body weight and BMI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Empagliflozin
- What this could lead to
- If it works, this could offer a way to manage weight gain and metabolic problems caused by olanzapine, making the antipsychotic safer and easier to tolerate.
- What could go wrong
- This is a small early-phase trial with only 40 participants, so results may not apply broadly. The drug may not reduce weight gain significantly, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta Unuversity
RECRUITINGTanta, 34518, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?